Description: Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Home Page: www.nuvectis.com
NVCT Technical Analysis
1 Bridge Plaza
Fort Lee,
NJ
07024
United States
Phone:
201 614 3150
Officers
| Name | Title |
|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & Pres |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Exec. VP, Chief Scientific & Bus. Officer |
| Mr. Shay Shemesh | Co-Founder, EVP, Chief Devel. & Operations Officer |
| Mr. Michael Carson CPA | VP of Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.3973 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |